Artesunate attenuates isoprenaline induced cardiac hypertrophy in rats via SIRT1 inhibiting NF-κB activation
European Journal of Pharmacology · 2024
DOI: 10.1016/j.ejphar.2024.176709 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Vaishnavi Golatkar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. Hauptthemen laut MEDLINE: Artesunate, Sirtuin 1, Isoproterenol, NF-kappa B. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Cardiac Hypertrophy is an adaptive response of the body to physiological and pathological stimuli, which increases cardiomyocyte size, thickening of cardiac muscles and progresses to heart failure. Downregulation of SIRT1 in cardiomyocytes has been linked with the pathogenesis of cardiac hypertrophy. The present study aimed to investigate the effect of Artesunate against isoprenaline induced cardiac hypertrophy in rats via SIRT1 inhibiting NF-κB activation. Experimental cardiac hypertrophy was induced in rats by subcutaneous administration of isoprenaline (5 mg/kg) for 14 days. Artesunate was administered simultaneously for 14 days at a dose of 25 mg/kg and 50 mg/kg. Artesunate administration showed significant dose dependent attenuation in mean arterial pressure, electrocardiogram, hypertrophy index and left ventricular wall thickness compared to the disease control group. It also alleviated cardiac injury biomarkers and oxidative stress. Histological observation showed amelioration of tissue injury in the artesunate treated groups compared to the disease control group. Further, artesunate treatment increased SIRT1 expression and decreased NF-kB expression in the heart. The results of the study show the cardioprotective effect of artesunate via SIRT1 inhibiting NF-κB activation in cardiomyocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.
- Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. Electronic address: lokesh.bhatt@bncp.ac.in.
Förderung
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Golatkar, V., & Bhatt, L. K. (2024). Artesunate attenuates isoprenaline induced cardiac hypertrophy in rats via SIRT1 inhibiting NF-κB activation. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2024.176709
Vancouver
Golatkar V, Bhatt LK. Artesunate attenuates isoprenaline induced cardiac hypertrophy in rats via SIRT1 inhibiting NF-κB activation. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176709
BibTeX
@article{Golatkar2024,
author = {Golatkar, Vaishnavi and Bhatt, Lokesh Kumar},
title = {Artesunate attenuates isoprenaline induced cardiac hypertrophy in rats via SIRT1 inhibiting NF-κB activation},
journal = {European Journal of Pharmacology},
year = {2024},
doi = {10.1016/j.ejphar.2024.176709}
}
EUVIMED